Last reviewed · How we verify
Repository corticotrophin
At a glance
| Generic name | Repository corticotrophin |
|---|---|
| Also known as | H.P. Acthar Gel |
| Sponsor | Arizona Kidney Disease and Hypertension Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Use of Acthar in Rheumatoid Arthritis (RA) Related Flares (PHASE4)
- ACTHar in the Treatment of Lupus Nephritis (PHASE4)
- Effects of ACTHAR on Advanced MRI Surrogate Markers of Disease Activity and on Comprehensive Immune Signature During MS Relapses (PHASE4)
- The Effects of Acthar on Synovial Inflammation in Rheumatoid Arthritis (PHASE3)
- Ocular Sarcoidosis Open Label Trial of ACTHAR Gel (NA)
- Adrenocorticotropic Hormone (ACTH) for Post-op Inflammation in Proliferative Vitreoretinopathy (PVR) (EARLY_PHASE1)
- Acthar Gel in Participants With Pulmonary Sarcoidosis (PHASE4)
- Adrenocorticotropic Hormone in Membranous Nephropathy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Repository corticotrophin CI brief — competitive landscape report
- Repository corticotrophin updates RSS · CI watch RSS
- Arizona Kidney Disease and Hypertension Center portfolio CI